Eli Casdin didn’t have to look very far to find a merger partner for the special purpose acquisition company that his firm, Casdin Capital, co-sponsored with Keith Meister’s Corvex Management earlier this year.
The blank-check company, CM Life Sciences III, on Friday announced that it is combining with EQRx, which describes itself as “a new type of pharmaceutical company” that promises to develop and deliver new drugs “at radically lower prices.”
Casdin,
